Keyphrases
Adverse Events
54%
Anti-PD-1
13%
B Cells
13%
Bavituximab
54%
Clinical Practice
54%
Complete Response
13%
Complication Rate
9%
Duration of Response
13%
Efficacy Assessment
31%
Estimated Blood Loss
18%
Fibrous Tissue
13%
Hepatocellular Carcinoma
13%
Immune Checkpoint
13%
Immune Checkpoint Inhibitors
100%
Immune Stimulation
13%
Immune-related Adverse Events
54%
Immunotherapy Efficacy
54%
Immunotherapy Toxicity
54%
Ipilimumab
18%
Length of Stay
18%
Median Progression-free Survival
13%
Nephrectomy
54%
Nivolumab
36%
Objective Response Rate
13%
Operative Time
18%
Overall Survival
13%
Pathological Response
54%
PD-1 Blockade
13%
Pembrolizumab
54%
Phase II Trial
54%
Processing Paradigm
10%
Programmed Death-ligand 1 (PD-L1)
13%
Progression-free Survival
13%
Renal Cell Carcinoma
54%
Response Rate
13%
Response-outcome
54%
Sematic
54%
Stimulatory Effect
13%
Surgical Margin
9%
Surgical Outcomes
54%
Synergistic Effect
13%
Targeting Antibodies
54%
Temporal Relations
13%
Therapeutic Strategies
13%
Treatment-related Adverse Events
13%
Tumor Microenvironment
13%
Tumor Response
13%
Tumor Specimens
13%
Unresectable Hepatocellular Carcinoma
54%
Variable Timing
54%
Medicine and Dentistry
Adverse Event
54%
Arm
10%
B Cell
10%
Bavituximab
54%
Biological Marker
10%
Biopsy
9%
Bleeding
18%
Cancer
9%
Clear Cell Renal Cell Carcinoma
54%
Hepatocellular Carcinoma
54%
Immune Checkpoint Inhibitor
65%
Immunotherapy
10%
Infusion
9%
Interventional Radiology Procedure
9%
Ipilimumab
18%
Metastasectomy
9%
Metastatic Carcinoma
9%
Monotherapy
9%
Neoplasm
21%
Nephrectomy
54%
Nivolumab
36%
Operation Duration
18%
Overall Survival
10%
Pembrolizumab
54%
Peroperative Complication
9%
Phosphatidylserine
54%
Progression Free Survival
21%
Progressive Disease
9%
Pulmonary Embolism
9%
Sepsis
9%
Stroma
10%
Surgical Margin
9%
Thrombectomy
9%
Tumor Microenvironment
10%